Abstract
The aim of this study is to establish the scientific benefit of royal jelly (RJ) on prostatic-specific antigen (PSA), post-void residual (PVR) volume and International Prostate Symptom Score (IPSS) in benign prostatic hyperplasia. For the study, a group of 40 men were administered 38 mg of RJ over a period of three months, their PSA values, prostate volumes and the volumes of their transitory prostate zones, PVR and IPPS values were measured at the end of the first month, and at the end of the third month. The results of this study confirm the potential of RJ in reducing PSA scores and improving IPSS values. Since the use of RJ did not lead to any significant reduction in PVR, prostate volume, or to any involution of the transitory zone, it appears that it may only affect the blood marker of prostatic hyperplasia and to improve quality-of-life (QoL) in those patients. Overall, in comparison to phytotherapy and conventional therapy, RJ had similar positive effects on QoL in patients with BPH, however it exhibited markedly better effects on reducing PSA levels in blood. The therapeutical use of RJ exhibited no side effects.
Declaration of interest
No part of this paper has been presented, published, or submitted for publication elsewhere in this or in any other language.
This clinical study was conducted in accordance with the principles laid down in the WMA Declaration of Helsinki along with the strict respect of patient’s rights and clinical study protocol. Patient confidentiality and data security is guaranteed.
Authors did not have any support in funding of the paper. The authors of this paper hereby declare that have not received nor shall receive any financial benefits from publishing the paper, neither have they received any financial incentive from a third party. We, the author and co-authors, hereby solemnly declare that we are not in any situation which could give rise to a conflict of interest.